

550 SYLVAN AVENUE, SUITE 101

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.

_	
	OMB APPROVAL
	OMB Number: 3235-0076
	Expires: August 31, 2015
	Estimated Average burden hours per response: 4.0

	washington, D.C.	response: 4.0	
1. Issuer's Identity			
CIK (Filer ID Number)	Previous Name(s) None	Entity Type	
0001412486	International Surf Resorts	0.0	
Name of Issuer	Inc.	© Corporation	
BIOZONE	International Surf Resorts,	C Limited Partnership	
PHARMACEUTICALS, INC.	Inc.	C Limited Liability Company	
Jurisdiction of Incorporation/Organization		C General Partnership	
NEVADA		C Business Trust	
Year of Incorporation/Organizatio	n	C Other	
Over Five Years Ago			
Within Last Five Years			
(Specify Year)			
1 et to be roi med			
2. Principal Place of Busi	ness and Contact Informa	tion	
Name of Issuer			
BIOZONE PHARMACEUTICALS,	INC.		
Street Address 1	Street Address 2		
550 SYLVAN AVENUE, SUITE 101			
City Sta	Principal Place of Business and Contact Information ne of Issuer  OZONE PHARMACEUTICALS, INC.  net Address 1  Street Address 2  O SYLVAN AVENUE, SUITE 101  State/Province/Country  ZIP/Postal Code  Phone No. of Issuer		
3 Related Persons			
5. Itolatoa 1 0150115			
Last Name	First Name	Middle Name	
Maza	Elliot	M.	
Street Address 1	Street Address 2		
550 SYLVAN AVENUE, SUITE	101		
City	State/Province/Country	ZIP/Postal Code	
ENGLEWOOD CLIFFS	NEW JERSEY	07632	
Relationship: Execut	ive Officer Director	Promoter	
	\		
Clarification of Response (if Necessary  Chief Executive Officer, Chief Finance			
Chief Executive Officer, Chief Finance	tal Officer and Secretary		
		20.00	
Last Name	First Name	Middle Name	
Prego-Novo	Roberto		
Street Address 1	Street Address 2		

City	S	tate/Province	/Country	ZIP/P	ostal Code
ENGLEWOOD CLIFFS		NEW JERSEY		07632	
Relationship:	Executive	e Officer	Director		Promoter
Clarification of Response	e (if Necessary)				
Chairman					
Last Name	F	irst Name		Middle	e Name
Keller		Brian		7	
Street Address 1			Street Address 2	=-1 !	
550 SYLVAN AVEN	UE, SUITE 10	1			
City	S	tate/Province	/Country	ZIP/Po	ostal Code
ENGLEWOOD CLIFF	S	NEW JERSE	ΣΥ	0763	2
1					
Relationship:	Executive	e Officer	<b>▼</b> Director		Promoter
			i Birecor		*
Clarification of Response					
President and Chief Scie	entific Officer				
Last Name	F	irst Name		Middle	e Name
Oertle		Christian			
Street Address 1			Street Address 2	2	
550 SYLVAN AVEN	UE, SUITE 10	1			
City	S	tate/Province	/Country	ZIP/P	ostal Code
ENGLEWOOD CLIFF	S	NEW JERSE	EΥ	0763	2
Relationship:	Executive	e Officer	☐ Director		Promoter
Clarification of December	(26 N )				
Chief Strategy Officer	e (II Necessary)				
Chief Strategy Officer					
4. Industry Grou	n				
	Ρ	Health C	Care	0 1	
C Agriculture		2000	technology	, F	Retailing
Banking & Financial		C Hea	alth Insurance	CF	Restaurants
C Commercial Ban	king	C Hos	spitals & Physicians	1	echnology
C Insurance		C Pha	armaceuticals	(	Computers
C Investing		C Oth	er Health Care		Telecommunications
C Investment Bank					Other Technology
C Pooled Investmen	nt Fund				
Other Banking &	Financial	_			ravel
7. E0		Manufac	_		Airlines & Airports
O Business Services		Real Est	ate nmercial		Lodging & Conventions
Energy		7000	nmercial istruction		Tourism & Travel Services
Coal Mining		> C01	iou ucuvii		Other Travel

C Residential Other Real Estate

C REITS & Finance

C Electric Utilities

C Energy Conservation

C Environmental Services

• Other

C Oil & Gas				
C Other Energy				
<b>7</b> 7 0'				
5. Issuer Size				
Revenue Range  No Revenues	Aggregate Net Asset Value Range  No Aggregate Net Asset Value			
0				
S1 - \$1,000,000 S1,000,001 - \$5,000,000	\$1 - \$5,000,000 \$5,000,001 - \$25,000,000			
\$5,000,001 - \$5,000,000	\$25,000,001 - \$20,000,000			
\$25,000,001 - \$25,000,000	S50,000,001 - \$50,000,000 S50,000,001 - \$100,000,000			
Over \$100,000,000	Over \$100,000,000			
© Decline to Disclose	C Decline to Disclose			
C Not Applicable	C Not Applicable			
Not Applicable	Not Applicable			
6. Federal Exemption(s)	and Exclusion(s) Claimed (select all that apply)			
Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505			
Rule 504 (b)(1)(i)				
Rule 504 (b)(1)(ii)				
Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)			
	Investment Company Act Section 3(c)			
New Notice Date of First Sa  Amendment	ale 2013-04-12 First Sale Yet to Occur			
8. Duration of Offering				
o. Duration of Offering				
Does the Issuer intend this offering to	last more than one year? C Yes No			
9 Type(s) of Securities (	Offered (select all that apply)			
Pooled Investment Fund				
Interests	iterests Equity			
Tenant-in-Common Securities Debt  Option, Warrant or Other Right to				
Acquire Another Security				
Security to be Acquired Upon  Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)			
10. Business Combinatio	n Transaction			
Is this offering being made in connecti transaction, such as a merger, acquisit	Yes No			
Clarification of Response (if Necessary	y)			

11. Minimum Investment				
Minimum investment accepted from any outside investor \$ 0 USD				
12. Sales Compensation				
Recipient CRD Number None				
Palladium Capital Advisors, LLC 129400				
(Associated) Broker or Dealer   None   (Associated) Broker or Dealer CRD   Number   None				
Street Address 1 Street Address 2				
230 PARK AVENUE, SUITE 539				
City State/Province/Country ZIP/Postal Code				
NEW YORK 10169				
State(s) of Solicitation All States Foreign/Non-US				
FLORIDA IILLINOIS NEW YORK TEXAS				
13. Offering and Sales Amounts				
Total Offering Amount \$ USD  Indefinite				
Total Amount Sold \$ 800000 USD				
Total Remaining to be \$ USD ▼ Indefinite				
Clarification of Response (if Necessary)				
Clai incation of Response (if Necessary)				
14. Investors				
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, Number of such non-accredited investors who already have invested in the offering  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:				
15. Sales Commissions & Finders' Fees Expenses				
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an				
expenditure is not known, provide an estimate and check the box next to the amount.  Sales Commissions \$ 26500 USD Estimate				
Finders' Fees \$ 0 USD Estimate				
Clarification of Response (if Necessary)				

## 16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$ 0	USD	<b>Estimate</b>

## Signature and Submission

Clarification of Response (if Necessary)

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

## **Terms of Submission**

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities
  described and undertaking to furnish them, upon written request, the information furnished to
  offerees
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
BIOZONE PHARMACEUTICAL INC.	S, /s/ Elliot Maza	Elliot Maza	Chief Executive Officer	2013-04-19